RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Merck & Company Incorporated

A collection of news and information related to Merck & Company Incorporated published by this site and its partners.

Top Merck & Company Incorporated Articles see all

Displaying items 1-5
  • Here's To Hartford's Modern Marvels

    Here's To Hartford's Modern Marvels
    Like many mid-sized cities, Hartford often seems to have an inferiority complex. But one thing the city does not need to feel inferior about is its collection of late 20th- and early 21st-century buildings designed by some of the nation's leading Modern architects. The list is long and includes buildings by Richard Meier, I.M. Pei, Robert Venturi, Cesar Pelli, Wallace Harrison and Kevin Roche.
  • Bristol-Myers sues Merck over U.S. immunotherapy patent

    (Reuters) - Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages. Immunotherapy is a mechanism that uses the body's own immune system to...

    Bristol-Myers demanda a Merck por patente de inmunoterapia en EEUU

    (Reuters) - La farmacéutica Bristol-Myers Squibb Co presentó una demanda el jueves contra Merck & Co Inc por la supuesta violación de su patente de inmunoterapia. La compañía está buscando una compensación por daños no especificada. La inmunoterapia es...

    Melanoma drug described as breakthrough gets FDA nod

    The Food and Drug Administration on Thursday gave its speedy approval to a treatment for melanoma that was found to shrink tumors by more than 30% in more than a third of patients with advanced cases of the deadly skin cancer. The FDA designated the...

    U.S. approves Merck immune-stimulating drug for melanoma

    (Reuters) - U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies. The decision...